These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17502787)

  • 1. Treatment-resistant depression: response to low-dose transdermal but not oral selegiline.
    Morgan PT
    J Clin Psychopharmacol; 2007 Jun; 27(3):313-4. PubMed ID: 17502787
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel transdermal delivery formulation of the monoamine oxidase inhibitor selegiline nearing release for treatment of depression.
    Thase ME
    J Clin Psychiatry; 2006 Apr; 67(4):671-2. PubMed ID: 16669733
    [No Abstract]   [Full Text] [Related]  

  • 3. Transdermal selegiline in patients receiving electroconvulsive therapy.
    Horn PJ; Reti I; Jayaram G
    Psychosomatics; 2010; 51(2):176-8. PubMed ID: 20332294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selegiline transdermal system Somerset.
    Mahmood I
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1230-3. PubMed ID: 12211421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules.
    Azzaro AJ; Ziemniak J; Kemper E; Campbell BJ; VanDenBerg C
    J Clin Pharmacol; 2007 Oct; 47(10):1256-67. PubMed ID: 17715422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First depression patch approved.
    FDA Consum; 2006; 40(3):4. PubMed ID: 16909484
    [No Abstract]   [Full Text] [Related]  

  • 7. Transdermal selegiline: new opportunity for managing depression.
    Tobe EH
    J Am Osteopath Assoc; 2008 Feb; 108(2):85-6. PubMed ID: 18303066
    [No Abstract]   [Full Text] [Related]  

  • 8. Psychopharmacology column: why choose selegiline transdermal system for refractory depression?
    Tobin M
    Issues Ment Health Nurs; 2007 Feb; 28(2):223-8. PubMed ID: 17365170
    [No Abstract]   [Full Text] [Related]  

  • 9. Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence.
    Elkashef A; Fudala PJ; Gorgon L; Li SH; Kahn R; Chiang N; Vocci F; Collins J; Jones K; Boardman K; Sather M
    Drug Alcohol Depend; 2006 Dec; 85(3):191-7. PubMed ID: 16730924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects.
    Azzaro AJ; Vandenberg CM; Blob LF; Kemper EM; Sharoky M; Oren DA; Campbell BJ
    J Clin Pharmacol; 2006 Aug; 46(8):933-44. PubMed ID: 16855078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new way to deliver psychiatric meds.
    Levin-Epstein M
    Behav Healthc; 2006 Aug; 26(8):22-3. PubMed ID: 16961036
    [No Abstract]   [Full Text] [Related]  

  • 12. Transdermal selegiline (Emsam).
    Med Lett Drugs Ther; 2006 May; 48(1235):41-2. PubMed ID: 16770292
    [No Abstract]   [Full Text] [Related]  

  • 13. Combined and selective monoamine oxidase inhibition in the treatment of depression in Parkinson's disease.
    Jansen Steur EN; Ballering LA
    Adv Neurol; 1999; 80():505-8. PubMed ID: 10410764
    [No Abstract]   [Full Text] [Related]  

  • 14. Selegiline transdermal system: a novel treatment option for major depressive disorder.
    Nandagopal JJ; DelBello MP
    Expert Opin Pharmacother; 2009 Jul; 10(10):1665-73. PubMed ID: 19527191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Long-term treatment of Parkinson's disease patients with selegiline hydrochloride (FPF 1100): outcome of 5-year treatment].
    Kondo T; Takubo H; Yokochi F; Okuma Y; Mizuno Y
    No To Shinkei; 2002 Dec; 54(12):1041-8. PubMed ID: 12599519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selegiline transdermal system: current awareness and promise.
    Pae CU; Lim HK; Han C; Neena A; Lee C; Patkar AA
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1153-63. PubMed ID: 17614182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study.
    Sacktor N; Schifitto G; McDermott MP; Marder K; McArthur JC; Kieburtz K
    Neurology; 2000 Jan; 54(1):233-5. PubMed ID: 10636157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transdermal selegiline.
    Patkar AA; Pae CU; Zarzar M
    Drugs Today (Barc); 2007 Jun; 43(6):361-77. PubMed ID: 17612708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of stress-induced deficit in aggression by monoamine oxidase inhibitors.
    Ossowska G; Klenk-Majewska B; Danilczuk Z; Wróbel A; Zebrowska-Lupina I
    Pol J Pharmacol; 1999; 51(5):391-7. PubMed ID: 10817539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAO inhibitors.
    Keller D
    Cleve Clin J Med; 2011 Feb; 78(2):81; author reply 81. PubMed ID: 21365960
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.